1 tracked superinvestor hold ASCENDIS PHARMA A/S - ADR (ASND), worth $179M combined, led by Brian Berghuis. Smart money is holding ASND as of the latest 13F filings.
Current price
$275.43
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$179M
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding ASND steady this quarter — buys and sells are balanced.
ASCENDIS PHARMA A/S - ADR (ASND) appears mainly in diversified and quant books here (1 funds, $179M combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Brian Berghuis at 0.9% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.9% | $179M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
Which superinvestors own ASND?
1 tracked funds hold ASCENDIS PHARMA A/S - ADR (ASND), the largest being Brian Berghuis (T. Rowe Price Mid-Cap Growth) at 0.9% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling ASND?
In the most recent 13F quarter, 0 tracked funds added or opened ASND and 0 trimmed it.
How much ASND do tracked funds hold?
Combined disclosed long exposure to ASND across tracked superinvestors is $179M as of the Mar 2026 filings.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Mar 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.